Coronavirus (COVID-19)
Learn more
A prospective, open-label phase 2 trial in metastatic pancreatic cancer subjects who have failed at least one line of any prior chemotherapy. The trial is designed to evaluate the of SM-88 therapy on pancreatic cancer and will measure multiple efficacy and safety endpoints, including overall response rate, overall survival, progression free survival, relevant biomarkers, quality of life and safety. In the initial stage of the trial (36 subjects), two dose levels of SM-88's metyrosine-derivative will be evaluated.
Eligibility Criteria:
This study is for patients age 18 and older.
Available at: Hospital of Central Connecticut
Referral Line: 860.972.4700
Get the latest healthcare news directly in your inbox.
To receive our health news text alerts / text StartHere to 85209